Your Rapid Respiratory Testing Solutions

Respiratory infection symptoms can be misleading, and can result in misdiagnosis, unnecessary tests, overuse of antimicrobials, and the continued spread of an infection throughout the community. When you need to diagnose a respiratory infection, you shouldn’t have to choose between speed and accuracy. With the help of rapid respiratory testing solutions from Alere, practitioners can quickly and accurately determine whether respiratory infections are self-limiting or require therapy. That can contribute to better treatment strategies, improved patient outcomes, and lower costs.

The sooner you know results, the more effectively you can manage respiratory care.

Respiratory infections pose a two-pronged threat to human health. Failure to treat patients quickly and appropriately could result in outbreaks and epidemics, while overuse of antibiotics can spur the emergence of antimicrobial-resistant infections.1, 2 Alere’s best-in-class respiratory products can help practitioners define appropriate treatment strategies fast, thus facilitating:

  • Improved patient and bed management during respiratory season
  • Reduced spread of nosocomial infections
  • Targeted treatment decisions, for better antimicrobial stewardship
  • Elimination of costly extra tests
Alere gives you the widest choice of rapid testing solutions for respiratory season.
Alere™ i Influenza A&B is the world’s first-ever CLIA-waived molecular, point-of-care test.3

Our Respiratory Testing Products

Rely on the market leader in rapid respiratory diagnostics.

We’re the world’s #1 maker of point-of-care (POC) infectious disease tests,4 offering an unmatched range of rapid respiratory point-of-care testing options. Our high-performance solutions help clinicians identify pathogens immediately and accurately, so they can determine appropriate treatment strategies sooner.

You can also find products using the Respiratory Symptom Product Lookup

Molecular Innovation

Bringing next-generation molecular technology to the point of care

Detecting the molecular signature (i.e., DNA) of a harmful organism at the point of care is fast becoming the most accurate and rapid way to identify infectious diseases, so that healthcare professionals can quickly initiate the correct course of therapy. However, most molecular tests rely on lab-based thermo cycling, which can slow time to treatment.

That’s why Alere created the ideal molecular platform for POC. Alere™ i combines the benefits of speed and accuracy. You no longer need to compromise when testing your patients and making clinical decisions. A rapid molecular result with Alere™ i means no longer having to choose. It provides accurate results in just minutes, so you can make immediate, appropriate clinical decisions. 

Alere™ i System

Molecular. In minutes.™ Get accurate results, faster than ever. So you can make confident, effective clinical decisions, sooner.

Alere™ i Influenza A & B

The first-ever CLIA-waived molecular rapid flu test. Delivers molecular flu results in less than 15 minutes on our unique Alere™ i platform.

Alere™ i Strep A

Faster than other molecular methods. More accurate than conventional rapid tests and provides results in 8 minutes or less.

Alere™ i RSV

First molecular rapid test to detect RSV within 13 minutes. The combined speed and accuracy you need to make real-time clinical decisions.

Improved Patient Management

Increasing effectiveness and efficiency through specificity.

According to the Centers for Disease Control and Prevention (CDC), the most frequent illness-related reason for doctor’s office visits is a cough.5 Such a common complaint can make patient management extremely complex. For example, the symptoms of influenza overlap with those of many other viral upper respiratory tract infections — so patients are often treated without a formal diagnosis. That can lead to a host of problems, including inappropriate prescriptions, needless tests, and inefficient bed management.

A specific diagnosis allows clinicians to avoid subjecting their patients to unnecessary tests, shortening hospital stays, and enables prompt initiation of appropriate supportive care.6, 7

Alere™ i RSV

First molecular rapid test to detect RSV within 13 minutes. The combined speed and accuracy you need to make real-time clinical decisions.

Alere BinaxNOW® S. pneumoniae Urinary Antigen Card

Used by medical professionals worldwide. This test provides accurate results in a timely manner allowing for appropriate therapy.

Control Infection Sooner

Prompt diagnosis is key to preventing cross-infection and outbreaks

Clinicians often have to make immediate treatment decisions based only on signs and symptoms due to poor access to sensitive, rapid diagnostic tests and long turnaround times for laboratory PCR results. If a contagious respiratory infection isn’t diagnosed in time, the health consequences can be dire for a community.

That’s why Alere’s respiratory solutions are designed to enable immediate diagnosis, right at the point of care. Our tests help you make real-time decisions on infection control and patient cohorting. So you can help reduce the risk of further infection of patients, medical staff, and others in the community.8, 9

Alere™ i System

Molecular. In minutes.™ Get accurate results, faster than ever. So you can make confident, effective clinical decisions, sooner.

Alere™ Reader

Rapid. Objective. Accurate. In just seconds, it accurately reads, interprets and transmits results of a range of Alere rapid lateral flow tests.

Alere BinaxNOW® S. pneumoniae Urinary Antigen Card

Used by medical professionals worldwide. This test provides accurate results in a timely manner allowing for appropriate therapy.

Combat Antimicrobial Resistance

Make targeted treatment decisions earlier with POC testing

Over-prescription of antibiotics has led to a global health crisis. Microbes are developing immunity to medications previously used to kill them. As a result, a growing number of infections are becoming harder to treat.

Rapid diagnostic tests are increasingly seen as vital to reducing antibiotic over-use.10 Alere is leading the way. Our breakthrough, best-in-class rapid diagnostics help practitioners quickly determine which respiratory tract infections (RTIs) require treatment, and which ones are self-limiting. By identifying pathogens at the point of care, you can make targeted treatment decisions sooner — reducing inappropriate antimicrobial use and the spread of resistance.

Alere BinaxNOW® Legionella Urinary Antigen Card

Quick, accurate detection of Legionnaires’ disease. It’s the only rapid Legionella urinary antigen test recommended under IDSA/ATS CAP Guidelines.

Alere BinaxNOW® S. pneumoniae Urinary Antigen Card

Used by medical professionals worldwide. This test provides accurate results in a timely manner allowing for appropriate therapy.

Clearview® RSV

Clearly different. Provides a simple, rapid, accurate method for the diagnosis of RSV in children less than 6 years and adults over age 60.

Alere™ i System

Molecular. In minutes.™ Get accurate results, faster than ever. So you can make confident, effective clinical decisions, sooner.

Alere BinaxNOW® Influenza A & B Card

Used by medical professionals worldwide. This test provides clear results that are easy to read, in just under 15 minutes.

Expand your knowledge

Fighting influenza with rapid molecular diagnostics

Timely and accurate diagnosis is essential for appropriate influenza treatment. Find out how we are making a positive difference in people’s lives.

Explore the Story

Fighting antibiotic resistance with rapid diagnostics

See how the use of existing rapid diagnostics and the development of new rapid diagnostics are critical components of the global strategy to combat antibiotic resistance.

Explore the Story

References